1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Preclinical and Clinical Trials Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Preclinical and Clinical Trials Market, by Phase/Study Type
8.1.1. Preclinical Studies
8.1.1.1. Market Revenue and Forecast
8.1.2. Phase I Clinical Trials
8.1.2.1. Market Revenue and Forecast
8.1.3. Phase II Clinical Trials
8.1.3.1. Market Revenue and Forecast
8.1.4. Phase III Clinical Trials
8.1.4.1. Market Revenue and Forecast
8.1.5. Phase IV/Post-Marketing Studies
8.1.5.1. Market Revenue and Forecast
9.1. Preclinical and Clinical Trials Market, by Therapeutic Area
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast
9.1.2. Cardiovascular Diseases
9.1.2.1. Market Revenue and Forecast
9.1.3. Infectious Diseases
9.1.3.1. Market Revenue and Forecast
9.1.4. Neurological Disorders:
9.1.4.1. Market Revenue and Forecast
9.1.5. Metabolic & Endocrine Disorders
9.1.5.1. Market Revenue and Forecast
9.1.6. Rare / Orphan Diseases
9.1.6.1. Market Revenue and Forecast
9.1.7. Other Therapeutic Areas
9.1.7.1. Market Revenue and Forecast
10.1. Preclinical and Clinical Trials Market, by Technology/Mode of Action
10.1.1. AI & Machine Learning in Trials
10.1.1.1. Market Revenue and Forecast
10.1.2. Electronic Data Capture (EDC) Platforms
10.1.2.1. Market Revenue and Forecast
10.1.3. Clinical Trial Management Systems (CTMS)
10.1.3.1. Market Revenue and Forecast
10.1.4. Wearable & Remote Monitoring Technologies
10.1.4.1. Market Revenue and Forecast
10.1.5. Other Digital & Automation Tools
10.1.5.1. Market Revenue and Forecast
11.1. Preclinical and Clinical Trials Market, by End-User
11.1.1. Pharmaceutical & Biotechnology Companies
11.1.1.1. Market Revenue and Forecast
11.1.2. Contract Research Organizations (CROs)
11.1.2.1. Market Revenue and Forecast
11.1.3. Academic & Research Institutes
11.1.3.1. Market Revenue and Forecast
11.1.4. Hospitals & Clinical Sites
11.1.4.1. Market Revenue and Forecast
11.1.5. Other End-Users
11.1.5.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Phase/Study Type
12.1.2. Market Revenue and Forecast, by Therapeutic Area
12.1.3. Market Revenue and Forecast, by Technology/Mode of Action
12.1.4. Market Revenue and Forecast, by End-User
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Phase/Study Type
12.1.5.2. Market Revenue and Forecast, by Therapeutic Area
12.1.5.3. Market Revenue and Forecast, by Technology/Mode of Action
12.1.5.4. Market Revenue and Forecast, by End-User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Phase/Study Type
12.1.6.2. Market Revenue and Forecast, by Therapeutic Area
12.1.6.3. Market Revenue and Forecast, by Technology/Mode of Action
12.1.6.4. Market Revenue and Forecast, by End-User
12.2. Europe
12.2.1. Market Revenue and Forecast, by Phase/Study Type
12.2.2. Market Revenue and Forecast, by Therapeutic Area
12.2.3. Market Revenue and Forecast, by Technology/Mode of Action
12.2.4. Market Revenue and Forecast, by End-User
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Phase/Study Type
12.2.5.2. Market Revenue and Forecast, by Therapeutic Area
12.2.5.3. Market Revenue and Forecast, by Technology/Mode of Action
12.2.5.4. Market Revenue and Forecast, by End-User
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Phase/Study Type
12.2.6.2. Market Revenue and Forecast, by Therapeutic Area
12.2.6.3. Market Revenue and Forecast, by Technology/Mode of Action
12.2.6.4. Market Revenue and Forecast, by End-User
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Phase/Study Type
12.2.7.2. Market Revenue and Forecast, by Therapeutic Area
12.2.7.3. Market Revenue and Forecast, by Technology/Mode of Action
12.2.7.4. Market Revenue and Forecast, by End-User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Phase/Study Type
12.2.8.2. Market Revenue and Forecast, by Therapeutic Area
12.2.8.3. Market Revenue and Forecast, by Technology/Mode of Action
12.2.8.4. Market Revenue and Forecast, by End-User
12.3. APAC
12.3.1. Market Revenue and Forecast, by Phase/Study Type
12.3.2. Market Revenue and Forecast, by Therapeutic Area
12.3.3. Market Revenue and Forecast, by Technology/Mode of Action
12.3.4. Market Revenue and Forecast, by End-User
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Phase/Study Type
12.3.5.2. Market Revenue and Forecast, by Therapeutic Area
12.3.5.3. Market Revenue and Forecast, by Technology/Mode of Action
12.3.5.4. Market Revenue and Forecast, by End-User
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Phase/Study Type
12.3.6.2. Market Revenue and Forecast, by Therapeutic Area
12.3.6.3. Market Revenue and Forecast, by Technology/Mode of Action
12.3.6.4. Market Revenue and Forecast, by End-User
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Phase/Study Type
12.3.7.2. Market Revenue and Forecast, by Therapeutic Area
12.3.7.3. Market Revenue and Forecast, by Technology/Mode of Action
12.3.7.4. Market Revenue and Forecast, by End-User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Phase/Study Type
12.3.8.2. Market Revenue and Forecast, by Therapeutic Area
12.3.8.3. Market Revenue and Forecast, by Technology/Mode of Action
12.3.8.4. Market Revenue and Forecast, by End-User
12.4. MEA
12.4.1. Market Revenue and Forecast, by Phase/Study Type
12.4.2. Market Revenue and Forecast, by Therapeutic Area
12.4.3. Market Revenue and Forecast, by Technology/Mode of Action
12.4.4. Market Revenue and Forecast, by End-User
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Phase/Study Type
12.4.5.2. Market Revenue and Forecast, by Therapeutic Area
12.4.5.3. Market Revenue and Forecast, by Technology/Mode of Action
12.4.5.4. Market Revenue and Forecast, by End-User
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Phase/Study Type
12.4.6.2. Market Revenue and Forecast, by Therapeutic Area
12.4.6.3. Market Revenue and Forecast, by Technology/Mode of Action
12.4.6.4. Market Revenue and Forecast, by End-User
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Phase/Study Type
12.4.7.2. Market Revenue and Forecast, by Therapeutic Area
12.4.7.3. Market Revenue and Forecast, by Technology/Mode of Action
12.4.7.4. Market Revenue and Forecast, by End-User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Phase/Study Type
12.4.8.2. Market Revenue and Forecast, by Therapeutic Area
12.4.8.3. Market Revenue and Forecast, by Technology/Mode of Action
12.4.8.4. Market Revenue and Forecast, by End-User
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Phase/Study Type
12.5.2. Market Revenue and Forecast, by Therapeutic Area
12.5.3. Market Revenue and Forecast, by Technology/Mode of Action
12.5.4. Market Revenue and Forecast, by End-User
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Phase/Study Type
12.5.5.2. Market Revenue and Forecast, by Therapeutic Area
12.5.5.3. Market Revenue and Forecast, by Technology/Mode of Action
12.5.5.4. Market Revenue and Forecast, by End-User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Phase/Study Type
12.5.6.2. Market Revenue and Forecast, by Therapeutic Area
12.5.6.3. Market Revenue and Forecast, by Technology/Mode of Action
12.5.6.4. Market Revenue and Forecast, by End-User
13.1. IQVIA
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. LabCorp Drug Development (Covance)
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Charles River Laboratories
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. ICON plc
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Parexel International
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. PPD, Inc. (Thermo Fisher)
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Syneos Health
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Medpace
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. WuXi AppTec
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. PRA Health Sciences
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
